[go: up one dir, main page]

WO2009011336A1 - Quinoline compounds - Google Patents

Quinoline compounds Download PDF

Info

Publication number
WO2009011336A1
WO2009011336A1 PCT/JP2008/062704 JP2008062704W WO2009011336A1 WO 2009011336 A1 WO2009011336 A1 WO 2009011336A1 JP 2008062704 W JP2008062704 W JP 2008062704W WO 2009011336 A1 WO2009011336 A1 WO 2009011336A1
Authority
WO
WIPO (PCT)
Prior art keywords
quinoline compounds
neuromedin
preventives
remedies
anxiety
Prior art date
Application number
PCT/JP2008/062704
Other languages
French (fr)
Japanese (ja)
Inventor
Shuji Saito
Tomoko Ishizaka
Yoshinori Sekiguchi
Original Assignee
Taisho Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co., Ltd. filed Critical Taisho Pharmaceutical Co., Ltd.
Publication of WO2009011336A1 publication Critical patent/WO2009011336A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Novel quinoline compounds represented by the general formula (I) which have neuromedin U-R2 receptor modulation activity, pharmaceutically acceptable salts thereof, or medicines containing them as the active ingredient are useful as preventives or remedies for stress-related diseases such as depression and anxiety; pain; or obesity.
PCT/JP2008/062704 2007-07-18 2008-07-14 Quinoline compounds WO2009011336A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007187652 2007-07-18
JP2007-187652 2007-07-18

Publications (1)

Publication Number Publication Date
WO2009011336A1 true WO2009011336A1 (en) 2009-01-22

Family

ID=40259669

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/062704 WO2009011336A1 (en) 2007-07-18 2008-07-14 Quinoline compounds

Country Status (1)

Country Link
WO (1) WO2009011336A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9394287B2 (en) 2010-11-05 2016-07-19 Senomyx, Inc. Compounds useful as modulators of TRPM8
US9732071B2 (en) 2015-10-01 2017-08-15 Senomyx, Inc. Compounds useful as modulators of TRPM8

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003105850A1 (en) * 2002-06-18 2003-12-24 Abbott Laboratories 2-aminoquinolines as melanin concentrating hormone receptor antagonists
JP2004300156A (en) * 2003-03-31 2004-10-28 Taisho Pharmaceut Co Ltd Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and therapeutic methods related to their use
JP2005518365A (en) * 2001-11-27 2005-06-23 メルク　エンド　カムパニー　インコーポレーテッド 4-aminoquinoline compounds
JP2005519876A (en) * 2001-11-27 2005-07-07 メルク　エンド　カムパニー　インコーポレーテッド 2-aminoquinoline compounds
JP2006124387A (en) * 2004-09-30 2006-05-18 Taisho Pharmaceut Co Ltd Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and therapeutic methods associated with the use thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005518365A (en) * 2001-11-27 2005-06-23 メルク　エンド　カムパニー　インコーポレーテッド 4-aminoquinoline compounds
JP2005519876A (en) * 2001-11-27 2005-07-07 メルク　エンド　カムパニー　インコーポレーテッド 2-aminoquinoline compounds
WO2003105850A1 (en) * 2002-06-18 2003-12-24 Abbott Laboratories 2-aminoquinolines as melanin concentrating hormone receptor antagonists
JP2004300156A (en) * 2003-03-31 2004-10-28 Taisho Pharmaceut Co Ltd Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and therapeutic methods related to their use
JP2006124387A (en) * 2004-09-30 2006-05-18 Taisho Pharmaceut Co Ltd Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and therapeutic methods associated with the use thereof

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9394287B2 (en) 2010-11-05 2016-07-19 Senomyx, Inc. Compounds useful as modulators of TRPM8
US10016418B2 (en) 2010-11-05 2018-07-10 Seaomyx, Inc. Compounds useful as modulators of TRPM8
US10953007B2 (en) 2010-11-05 2021-03-23 Firmenich Incorporated Compounds useful as modulators of TRPM8
US9732071B2 (en) 2015-10-01 2017-08-15 Senomyx, Inc. Compounds useful as modulators of TRPM8

Similar Documents

Publication Publication Date Title
WO2008051942A3 (en) Farnesoid x receptor agonists
WO2009017822A3 (en) Pi3 kinase modulators and methods of use
WO2009111700A3 (en) Oxadiazoanthracene compounds for the treatment of diabetes
WO2007076260A3 (en) Farnesoid x receptor agonists
PT2150530E (en) Substituted sulfonamide derivatives
WO2009156462A3 (en) Organic compounds
WO2007135527A3 (en) Benzimidazolyl compounds
WO2009016410A3 (en) Chemical compounds 831
WO2009024611A3 (en) 4-benzylaminoquinolines, pharmaceutical compositions containing them and their use
MX2007014892A (en) Polymorphs of ethyl 3-[(2-{[4-(hexyloxycarbonylamino-iminomethyl) phenylamino]methyl}-1-methyl-1h-benzimidazole-5-carbonyl)pyridin -2-ylamino]propionate.
WO2009051119A1 (en) Pyrimidyl indoline compound
PT2043600T (en) Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic
WO2007044796A3 (en) Pyridazinone compounds as calcilytics
UA103930C2 (en) Normal;heading 1;heading 2;heading 3;COMPOUNDS AND COMPOSITION FOR THE TREATMENT OF PARASITIC DISEASES
WO2009025785A3 (en) Cb2 receptor ligands for the treatment of pain
WO2010052144A3 (en) Neuropeptide-2-receptor (y-2r) agonists and uses thereof
WO2008059370A8 (en) Substituted bicyclocarboxyamide compounds
WO2007090661A3 (en) Active substance combination comprising azolylcarbinol compounds
WO2009013545A3 (en) Chemical compounds
WO2008050199A3 (en) Substituted phenylmethyl bicyclocarboxyamide compounds
WO2011045232A3 (en) Neuropeptide-2 receptor (y-2r) agonists
WO2009105969A8 (en) Epothilone analogues, their pharmaceutical compositions, their use and their preparations
WO2007095039A3 (en) Pharmaceutical formulations
WO2008116663A3 (en) Heterocyclyl-substituted-tetrahydro-naphthalen-amine derivatives, their preparation and use as medicaments
WO2008131946A3 (en) Substituted amide derivatives

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08791129

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08791129

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP